Immunotherapy of prostate cancer

Stephen J. Freedland, Allan J. Pantuck, Jeffrey Weider, Amnon Zisman, Arie S. Belldegrun

Research output: Contribution to journalArticlepeer-review


The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.

Original languageEnglish
Pages (from-to)242-247
Number of pages6
JournalCurrent Urology Reports
Issue number3
StatePublished - May 2001
Externally publishedYes


  • Dendritic Cell
  • Epidermal Growth Factor Receptor
  • Human Clinical Trial
  • Prostatic Acid Phosphatase
  • Tumor Vaccine


Dive into the research topics of 'Immunotherapy of prostate cancer'. Together they form a unique fingerprint.

Cite this